>>>welcome visitor, haven't logged in. Login
Subscribe Now Contact us  
Font Size:  A A A Search “Fabao” Window English 中文 = 简体  繁体
  Favorite   DownLoad   Print
 
Notice of the General Office of the China Food and Drug Administration on the Work concerning the Implementation of the Decision of the State Council on Cancelling the Third Group of Administrative Licensing Items Designated by the Central Government for Implementation by Local Governments [Effective]
国家食品药品监管总局办公厅关于落实《国务院第三批取消中央指定地方实施行政许可事项的决定》有关工作的通知 [现行有效]
【法宝引证码】

Notice of the General Office of the China Food and Drug Administration on the Work concerning the Implementation of the Decision of the State Council on Cancelling the Third Group of Administrative Licensing Items Designated by the Central Government for Implementation by Local Governments 

国家食品药品监管总局办公厅关于落实《国务院第三批取消中央指定地方实施行政许可事项的决定》有关工作的通知

(No. 46 [2017] of the General Office of the China Food and Drug Administration) (食药监办法〔2017〕46号)

Food and drug administrations of all provinces, autonomous regions, and municipalities directly under the Central Government and the Food and Drug Administration of Xinjiang Production and Construction Corps: 各省、自治区、直辖市食品药品监督管理局,新疆生产建设兵团食品药品监督管理局:
On January 21, 2017, the State Council issued the Decision of the State Council on Cancelling the Third Group of Administrative Licensing Items Designated by the Central Government for Implementation by Local Governments (No. 7 [2017], State Council), which cancelled three administrative licensing items: the approval of registration of pharmaceutical excipients (excluding new and imported ones), the preliminary examination of the accreditation of institutions for drug clinical trials as well as the approval of Internet-based pharmaceutical trading service enterprises (excluding third-party platforms) by provincial food and drug administrative departments. In order to implement the relevant requirements for canceling the administrative licensing items, and effectively complete the implementation and transition of the interim and ex post supervision measures, you are hereby notified of relevant issues as follows: 2017年1月21日,国务院发布了《第三批取消中央指定地方实施行政许可事项的决定》(国发〔2017〕7号),取消了由省级食品药品监管部门实施的药用辅料(不含新药用辅料和进口药用辅料)注册审批、药物临床试验机构资格认定初审、互联网药品交易服务企业审批(第三方平台除外)三项行政许可事项。为了落实取消行政许可事项的相关要求,做好事中事后监管措施的落实和衔接工作,现就有关事项通知如下:
I. Cancellation of the approval of registration of pharmaceutical excipients (excluding new and imported ones) by provincial food and drug administrative departments   一、关于取消省级食品药品监管部门实施的药用辅料(不含新药用辅料和进口药用辅料)注册审批
The provincial food and drug administrative departments shall complete the related review and approval of pharmaceutical excipients, and effectively conduct the work such as on-site inspection and sampling of domestic high-risk pharmaceutical excipients in accordance with the Announcement on Matters concerning the Related Review and Approval of Drug Packaging Materials, Pharmaceutical Excipients, and Drugs (No. 134 [2016]). They shall effectively strengthen the routine supervision over the manufacturers of pharmaceutical excipients, and intensify the extended inspection on pharmaceutical excipients so as to guarantee the quality of drugs. 各省级食品药品监管部门应按照《关于药包材药用辅料与药品关联审评审批有关事项的公告》(2016年第134号)要求,落实药用辅料关联审评审批工作,做好国产高风险药用辅料的现场核查、抽样等工作。要切实加强对药用辅料生产企业的日常监管,强化对药用辅料的延伸检查,保证药品质量。
II. Cancellation of the preliminary examination of the accreditation of institutions for drug clinical trials by provincial food and drug administrative departments   二、关于取消省级食品药品监管部门实施的药物临床试验机构资格认定初审
The accreditation of institutions for drug clinical trials and the review thereof shall be accepted by the China Food and Drug Administration (“CFDA”), and the examination opinions of a provincial health administrative department and a provincial food and drug administrative department are not required to be submitted with application materials. An applicant shall respectively log onto the CFDA's electronic application system and review system for the accreditation of institutions for drug clinical trials to fill out a written application and application materials as required, and mail paper materials to the Center for Food and Drug Inspection of the CFDA. Upon formal examination, the CFDA will notify in writing the applicant of whether to accept the application or not. The applicant will be informed of the on-site inspection and examination results in writing, and the CFDA will make an announcement on the applicant accredited and issue a certificate.
......
 药物临床试验机构资格认定和复核检查由食品药品监管总局(以下简称总局)受理,申请资料中无需提交省级卫生行政部门和省级食品药品监管部门审核意见。申请人分别登陆总局药物临床试验机构资格认定电子申请系统和复核检查系统,按要求填报申请书和申请材料,纸质资料寄至总局核查中心,总局形式审查后将书面通知申请人是否受理。现场检查和审核的结果将书面通知申请人,总局对通过资格认定的申请人情况进行公告并颁发证书。
......

Dear visitor, as a premium member of this database, you will get complete access to all content.Please go premium and get more.

1. To become a premium member, please call 400-810-8266 Ext. 171.

2. Binding to the account with access to this database.

3. Apply for a trial account.

4. To get instant access to a document, you can Pay Amount 【¥200.00】 for your single purchase.
 
您好:您现在要进入的是北大法宝英文库会员专区。
如您是我们英文用户可直接 登录,进入会员专区查询您所需要的信息;如您还不是我们 的英文用户;您可通过网上支付进行单篇购买,支付成功后即可立即查看本篇内容。
Tel: +86 (10) 82689699, +86 (10) 82668266 ext. 153
Mobile: +86 13311570713
Fax: +86 (10) 82668268
E-mail:info@chinalawinfo.com
     
     
Scan QR Code and Read on Mobile
【法宝引证码】        北大法宝en.pkulaw.cn
Message: Please kindly comment on the present translation.
 
Confirmation Code:
Click image to reset code
 
  Translations are by lawinfochina.com, and we retain exclusive copyright over content found on our website except for content we publish as authorized by respective copyright owners or content that is publicly available from government sources.

Due to differences in language, legal systems, and culture, English translations of Chinese law are for reference purposes only. Please use the official Chinese-language versions as the final authority. Lawinfochina.com and its staff will not be directly or indirectly liable for use of materials found on this website.

We welcome your comments and suggestions, which assist us in continuing to improve the quality of our materials as we dynamically expand content.
 
Home | About us | Disclaimer | Chinese